Financing channel feed – Endpoints News

Financing channel feed

As Covid-19 shifts the world's attention to biotech, Noubar Afeyan's Flagship builds $3.4B fund to fuel new inventions. Here's the plan

4 years ago

The IPO 4-1-1: Four filings, a pricing and a withdrawal headline this week's Nasdaq action as raise approaches $7.5B

4 years ago

Fresh off $598M deal with Novo Nordisk, a Japanese stem cell company is on its way to the clinic with a different approach to treating heart failure

4 years ago

Versant-backed Bright Peak sets a date to bring its IL-2 into the clinic — but all eyes are on an IPO after latest mega-round drops

4 years ago

Synthekine nabs megaround in bid to edge out Merck, Sanofi in IL-2 sprint

4 years ago

The Flagship train keeps chugging with its 'intersystems' player eyeing the clinic next year with 3 new drugs

4 years ago

A Medicxi-backed startup looks to tackle treatment-resistant blood cancers, and it's going after AML first

4 years ago

A gene therapy biotech is bursting onto the scene with 12 programs in tow. An ultra-rare neuro disease is up first

4 years ago

ViaCyte adds to the war chest in what looks like an IPO-bound effort to bring regenerative medicine to diabetes

4 years ago

Flagship and Khosla Ventures team up for biotech's latest SPAC, with Valo Health winning a blank check ticket to Nasdaq

4 years ago

Polaris, AbbVie, Bayer back Stuart Schreiber's hunt to turn cancer treatments into cures

4 years ago

From protein degradation to 'toad venom': Another five biotechs will make the Nasdaq shuffle after filing SEC paperwork

5 years ago

Dermavant engineers $160M deal to pay off GlaxoSmithKline milestones, gear up to launch psoriasis cream

5 years ago

A Celltrion-backed biotech is developing 'tunable' conjugates to crack solid tumors — and it has eyes on the clinic

5 years ago

Corey Goodman's venBio closes latest VC fund — this time to the tune of $550M — with a dozen or more investments on deck

5 years ago

Salvaging 'ugly fruit': After a series of protein degradation bets, Versant turns to protein stabilization platform out of Columbia

5 years ago

Chamath Palihapitiya, the outspoken 'King of SPACs,' turns his eyes to biotech with plans to cash an $800M blank check

5 years ago

BARDA looks to get the jump on next pandemic with VC arm targeting 'transformative' tech

5 years ago

Almost a decade after identifying a new class of RNA, a group of scientists sparks interest from Takeda Ventures

5 years ago

Five more biotechs file their SEC paperwork as the IPO Class of 2021 swells to 60

5 years ago

Exclusive: Helsinn chief Riccardo Braglia spells out a blockbuster plan to take the family pharma public — with an eye on new cancer drug deals, spinout

5 years ago

With two debuts and a SPAC, biopharma notches another busy week as IPO raise soars past $7B

5 years ago

Frazier reloads with $1.4B to bet on 'growth buyout' plays — nearly double the last fund

5 years ago

Novo Holdings, Vivo lead a record $200M raise for a Singapore-based tools player with plans for a Boston hub, new deals

5 years ago

First page Previous page 74 75 767778 79 80 Next page Last page